nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP2D6—Hydroxyurea—head and neck cancer	0.224	0.55	CbGbCtD
Duloxetine—CYP1A2—Fluorouracil—head and neck cancer	0.104	0.255	CbGbCtD
Duloxetine—CYP2D6—Vinblastine—head and neck cancer	0.0795	0.195	CbGbCtD
Duloxetine—Oliguria—Docetaxel—head and neck cancer	0.00292	0.00548	CcSEcCtD
Duloxetine—Infestation NOS—Hydroxyurea—head and neck cancer	0.0029	0.00543	CcSEcCtD
Duloxetine—Infestation—Hydroxyurea—head and neck cancer	0.0029	0.00543	CcSEcCtD
Duloxetine—Haemoglobin—Vinblastine—head and neck cancer	0.00287	0.00538	CcSEcCtD
Duloxetine—Haemorrhage—Vinblastine—head and neck cancer	0.00285	0.00535	CcSEcCtD
Duloxetine—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00284	0.00534	CcSEcCtD
Duloxetine—Hypoaesthesia—Vinblastine—head and neck cancer	0.00284	0.00532	CcSEcCtD
Duloxetine—Pharyngitis—Vinblastine—head and neck cancer	0.00283	0.00531	CcSEcCtD
Duloxetine—Stomatitis—Hydroxyurea—head and neck cancer	0.00282	0.0053	CcSEcCtD
Duloxetine—Cardiac failure—Fluorouracil—head and neck cancer	0.00277	0.0052	CcSEcCtD
Duloxetine—Lethargy—Fluorouracil—head and neck cancer	0.00276	0.00518	CcSEcCtD
Duloxetine—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00274	0.00514	CcSEcCtD
Duloxetine—Osteoarthritis—Fluorouracil—head and neck cancer	0.00271	0.00508	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00271	0.00508	CcSEcCtD
Duloxetine—Blood pressure increased—Docetaxel—head and neck cancer	0.00269	0.00505	CcSEcCtD
Duloxetine—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00269	0.00505	CcSEcCtD
Duloxetine—Haemoglobin—Hydroxyurea—head and neck cancer	0.00261	0.0049	CcSEcCtD
Duloxetine—Influenza like illness—Docetaxel—head and neck cancer	0.00261	0.0049	CcSEcCtD
Duloxetine—Haemorrhage—Hydroxyurea—head and neck cancer	0.0026	0.00488	CcSEcCtD
Duloxetine—Hallucination—Hydroxyurea—head and neck cancer	0.00259	0.00485	CcSEcCtD
Duloxetine—Colitis—Docetaxel—head and neck cancer	0.00258	0.00485	CcSEcCtD
Duloxetine—Irritability—Fluorouracil—head and neck cancer	0.00258	0.00484	CcSEcCtD
Duloxetine—Ataxia—Fluorouracil—head and neck cancer	0.00254	0.00477	CcSEcCtD
Duloxetine—Alopecia—Vinblastine—head and neck cancer	0.00252	0.00473	CcSEcCtD
Duloxetine—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00242	0.00454	CcSEcCtD
Duloxetine—Muscular weakness—Fluorouracil—head and neck cancer	0.00239	0.00448	CcSEcCtD
Duloxetine—Angiopathy—Hydroxyurea—head and neck cancer	0.00236	0.00443	CcSEcCtD
Duloxetine—Dysphagia—Fluorouracil—head and neck cancer	0.00234	0.00439	CcSEcCtD
Duloxetine—Chills—Hydroxyurea—head and neck cancer	0.00233	0.00438	CcSEcCtD
Duloxetine—Ill-defined disorder—Vinblastine—head and neck cancer	0.0023	0.00432	CcSEcCtD
Duloxetine—Alopecia—Hydroxyurea—head and neck cancer	0.0023	0.00431	CcSEcCtD
Duloxetine—Anaemia—Vinblastine—head and neck cancer	0.00229	0.0043	CcSEcCtD
Duloxetine—Phlebitis—Docetaxel—head and neck cancer	0.00227	0.00425	CcSEcCtD
Duloxetine—Erythema—Hydroxyurea—head and neck cancer	0.00226	0.00425	CcSEcCtD
Duloxetine—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00224	0.00421	CcSEcCtD
Duloxetine—Malaise—Vinblastine—head and neck cancer	0.00224	0.0042	CcSEcCtD
Duloxetine—Vertigo—Vinblastine—head and neck cancer	0.00223	0.00418	CcSEcCtD
Duloxetine—Leukopenia—Vinblastine—head and neck cancer	0.00222	0.00417	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00217	0.00408	CcSEcCtD
Duloxetine—Hepatic failure—Docetaxel—head and neck cancer	0.00217	0.00408	CcSEcCtD
Duloxetine—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00215	0.00404	CcSEcCtD
Duloxetine—Convulsion—Vinblastine—head and neck cancer	0.00215	0.00403	CcSEcCtD
Duloxetine—Hypertension—Vinblastine—head and neck cancer	0.00214	0.00402	CcSEcCtD
Duloxetine—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00213	0.004	CcSEcCtD
Duloxetine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.0021	0.00394	CcSEcCtD
Duloxetine—Anaemia—Hydroxyurea—head and neck cancer	0.00209	0.00393	CcSEcCtD
Duloxetine—Discomfort—Vinblastine—head and neck cancer	0.00209	0.00392	CcSEcCtD
Duloxetine—Hot flush—Docetaxel—head and neck cancer	0.00209	0.00392	CcSEcCtD
Duloxetine—Infestation NOS—Fluorouracil—head and neck cancer	0.00208	0.00391	CcSEcCtD
Duloxetine—Infestation—Fluorouracil—head and neck cancer	0.00208	0.00391	CcSEcCtD
Duloxetine—Menopausal symptoms—Docetaxel—head and neck cancer	0.00207	0.00388	CcSEcCtD
Duloxetine—Visual disturbance—Docetaxel—head and neck cancer	0.00206	0.00387	CcSEcCtD
Duloxetine—Atrial fibrillation—Docetaxel—head and neck cancer	0.00206	0.00387	CcSEcCtD
Duloxetine—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00206	0.00386	CcSEcCtD
Duloxetine—Renal impairment—Docetaxel—head and neck cancer	0.00205	0.00385	CcSEcCtD
Duloxetine—Myocardial infarction—Fluorouracil—head and neck cancer	0.00204	0.00383	CcSEcCtD
Duloxetine—Malaise—Hydroxyurea—head and neck cancer	0.00204	0.00383	CcSEcCtD
Duloxetine—Stomatitis—Fluorouracil—head and neck cancer	0.00203	0.00381	CcSEcCtD
Duloxetine—Urinary tract infection—Fluorouracil—head and neck cancer	0.00203	0.0038	CcSEcCtD
Duloxetine—Conjunctivitis—Fluorouracil—head and neck cancer	0.00203	0.0038	CcSEcCtD
Duloxetine—Leukopenia—Hydroxyurea—head and neck cancer	0.00203	0.0038	CcSEcCtD
Duloxetine—Cardiac failure—Docetaxel—head and neck cancer	0.002	0.00375	CcSEcCtD
Duloxetine—Lethargy—Docetaxel—head and neck cancer	0.00199	0.00374	CcSEcCtD
Duloxetine—Thrombocytopenia—Vinblastine—head and neck cancer	0.00198	0.00372	CcSEcCtD
Duloxetine—Epistaxis—Fluorouracil—head and neck cancer	0.00197	0.00369	CcSEcCtD
Duloxetine—Convulsion—Hydroxyurea—head and neck cancer	0.00196	0.00368	CcSEcCtD
Duloxetine—Hyponatraemia—Docetaxel—head and neck cancer	0.00196	0.00368	CcSEcCtD
Duloxetine—Pain in extremity—Docetaxel—head and neck cancer	0.00195	0.00366	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00195	0.00366	CcSEcCtD
Duloxetine—Anorexia—Vinblastine—head and neck cancer	0.00193	0.00362	CcSEcCtD
Duloxetine—Migraine—Docetaxel—head and neck cancer	0.00192	0.00361	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00191	0.00359	CcSEcCtD
Duloxetine—Discomfort—Hydroxyurea—head and neck cancer	0.0019	0.00357	CcSEcCtD
Duloxetine—Haemoglobin—Fluorouracil—head and neck cancer	0.00188	0.00353	CcSEcCtD
Duloxetine—Haemorrhage—Fluorouracil—head and neck cancer	0.00187	0.00351	CcSEcCtD
Duloxetine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00186	0.00349	CcSEcCtD
Duloxetine—Pharyngitis—Fluorouracil—head and neck cancer	0.00186	0.00349	CcSEcCtD
Duloxetine—Oedema—Hydroxyurea—head and neck cancer	0.00185	0.00347	CcSEcCtD
Duloxetine—Ataxia—Docetaxel—head and neck cancer	0.00184	0.00344	CcSEcCtD
Duloxetine—Infection—Hydroxyurea—head and neck cancer	0.00184	0.00344	CcSEcCtD
Duloxetine—Paraesthesia—Vinblastine—head and neck cancer	0.00182	0.00341	CcSEcCtD
Duloxetine—Dehydration—Docetaxel—head and neck cancer	0.00182	0.00341	CcSEcCtD
Duloxetine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00181	0.0034	CcSEcCtD
Duloxetine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00181	0.00339	CcSEcCtD
Duloxetine—Liver function test abnormal—Docetaxel—head and neck cancer	0.0018	0.00338	CcSEcCtD
Duloxetine—Skin disorder—Hydroxyurea—head and neck cancer	0.00179	0.00337	CcSEcCtD
Duloxetine—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00178	0.00335	CcSEcCtD
Duloxetine—Abdominal pain upper—Docetaxel—head and neck cancer	0.00178	0.00335	CcSEcCtD
Duloxetine—Breast disorder—Docetaxel—head and neck cancer	0.00176	0.00331	CcSEcCtD
Duloxetine—Anorexia—Hydroxyurea—head and neck cancer	0.00176	0.0033	CcSEcCtD
Duloxetine—Decreased appetite—Vinblastine—head and neck cancer	0.00176	0.0033	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00176	0.0033	CcSEcCtD
Duloxetine—Cramp muscle—Docetaxel—head and neck cancer	0.00176	0.0033	CcSEcCtD
Duloxetine—Nasopharyngitis—Docetaxel—head and neck cancer	0.00175	0.00328	CcSEcCtD
Duloxetine—Pain—Vinblastine—head and neck cancer	0.00173	0.00325	CcSEcCtD
Duloxetine—Constipation—Vinblastine—head and neck cancer	0.00173	0.00325	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00172	0.00323	CcSEcCtD
Duloxetine—Dysphagia—Docetaxel—head and neck cancer	0.00169	0.00317	CcSEcCtD
Duloxetine—Arrhythmia—Fluorouracil—head and neck cancer	0.00167	0.00314	CcSEcCtD
Duloxetine—Feeling abnormal—Vinblastine—head and neck cancer	0.00167	0.00313	CcSEcCtD
Duloxetine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00166	0.00311	CcSEcCtD
Duloxetine—Alopecia—Fluorouracil—head and neck cancer	0.00165	0.0031	CcSEcCtD
Duloxetine—Somnolence—Hydroxyurea—head and neck cancer	0.00164	0.00308	CcSEcCtD
Duloxetine—Erythema—Fluorouracil—head and neck cancer	0.00163	0.00306	CcSEcCtD
Duloxetine—Dyspepsia—Hydroxyurea—head and neck cancer	0.00163	0.00305	CcSEcCtD
Duloxetine—Decreased appetite—Hydroxyurea—head and neck cancer	0.00161	0.00301	CcSEcCtD
Duloxetine—Abdominal pain—Vinblastine—head and neck cancer	0.0016	0.003	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00159	0.00299	CcSEcCtD
Duloxetine—Fatigue—Hydroxyurea—head and neck cancer	0.00159	0.00299	CcSEcCtD
Duloxetine—Constipation—Hydroxyurea—head and neck cancer	0.00158	0.00296	CcSEcCtD
Duloxetine—Pain—Hydroxyurea—head and neck cancer	0.00158	0.00296	CcSEcCtD
Duloxetine—Weight increased—Docetaxel—head and neck cancer	0.00154	0.00288	CcSEcCtD
Duloxetine—Vision blurred—Fluorouracil—head and neck cancer	0.00154	0.00288	CcSEcCtD
Duloxetine—Weight decreased—Docetaxel—head and neck cancer	0.00153	0.00286	CcSEcCtD
Duloxetine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00152	0.00286	CcSEcCtD
Duloxetine—Anaemia—Fluorouracil—head and neck cancer	0.00151	0.00283	CcSEcCtD
Duloxetine—Infestation NOS—Docetaxel—head and neck cancer	0.0015	0.00282	CcSEcCtD
Duloxetine—Infestation—Docetaxel—head and neck cancer	0.0015	0.00282	CcSEcCtD
Duloxetine—Hypersensitivity—Vinblastine—head and neck cancer	0.00149	0.0028	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.00149	0.0028	CcSEcCtD
Duloxetine—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00148	0.00278	CcSEcCtD
Duloxetine—Renal failure—Docetaxel—head and neck cancer	0.00148	0.00278	CcSEcCtD
Duloxetine—Myocardial infarction—Docetaxel—head and neck cancer	0.00148	0.00277	CcSEcCtD
Duloxetine—Jaundice—Docetaxel—head and neck cancer	0.00147	0.00275	CcSEcCtD
Duloxetine—Stomatitis—Docetaxel—head and neck cancer	0.00147	0.00275	CcSEcCtD
Duloxetine—Conjunctivitis—Docetaxel—head and neck cancer	0.00146	0.00274	CcSEcCtD
Duloxetine—Body temperature increased—Hydroxyurea—head and neck cancer	0.00146	0.00274	CcSEcCtD
Duloxetine—Leukopenia—Fluorouracil—head and neck cancer	0.00146	0.00274	CcSEcCtD
Duloxetine—Asthenia—Vinblastine—head and neck cancer	0.00145	0.00273	CcSEcCtD
Duloxetine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00142	0.00267	CcSEcCtD
Duloxetine—Epistaxis—Docetaxel—head and neck cancer	0.00142	0.00266	CcSEcCtD
Duloxetine—Convulsion—Fluorouracil—head and neck cancer	0.00141	0.00265	CcSEcCtD
Duloxetine—Chest pain—Fluorouracil—head and neck cancer	0.00139	0.0026	CcSEcCtD
Duloxetine—Myalgia—Fluorouracil—head and neck cancer	0.00139	0.0026	CcSEcCtD
Duloxetine—Diarrhoea—Vinblastine—head and neck cancer	0.00139	0.0026	CcSEcCtD
Duloxetine—Discomfort—Fluorouracil—head and neck cancer	0.00137	0.00257	CcSEcCtD
Duloxetine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00136	0.00255	CcSEcCtD
Duloxetine—Haemoglobin—Docetaxel—head and neck cancer	0.00136	0.00255	CcSEcCtD
Duloxetine—Haemorrhage—Docetaxel—head and neck cancer	0.00135	0.00253	CcSEcCtD
Duloxetine—Hepatitis—Docetaxel—head and neck cancer	0.00135	0.00253	CcSEcCtD
Duloxetine—Hypoaesthesia—Docetaxel—head and neck cancer	0.00134	0.00252	CcSEcCtD
Duloxetine—Confusional state—Fluorouracil—head and neck cancer	0.00134	0.00252	CcSEcCtD
Duloxetine—Pharyngitis—Docetaxel—head and neck cancer	0.00134	0.00252	CcSEcCtD
Duloxetine—Dizziness—Vinblastine—head and neck cancer	0.00134	0.00251	CcSEcCtD
Duloxetine—Urinary tract disorder—Docetaxel—head and neck cancer	0.00133	0.0025	CcSEcCtD
Duloxetine—Oedema peripheral—Docetaxel—head and neck cancer	0.00133	0.0025	CcSEcCtD
Duloxetine—Oedema—Fluorouracil—head and neck cancer	0.00133	0.00249	CcSEcCtD
Duloxetine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00133	0.00249	CcSEcCtD
Duloxetine—Connective tissue disorder—Docetaxel—head and neck cancer	0.00133	0.00249	CcSEcCtD
Duloxetine—Asthenia—Hydroxyurea—head and neck cancer	0.00133	0.00249	CcSEcCtD
Duloxetine—Urethral disorder—Docetaxel—head and neck cancer	0.00132	0.00248	CcSEcCtD
Duloxetine—Infection—Fluorouracil—head and neck cancer	0.00132	0.00248	CcSEcCtD
Duloxetine—Nervous system disorder—Fluorouracil—head and neck cancer	0.0013	0.00245	CcSEcCtD
Duloxetine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.0013	0.00244	CcSEcCtD
Duloxetine—Visual impairment—Docetaxel—head and neck cancer	0.0013	0.00244	CcSEcCtD
Duloxetine—Tachycardia—Fluorouracil—head and neck cancer	0.0013	0.00243	CcSEcCtD
Duloxetine—Vomiting—Vinblastine—head and neck cancer	0.00129	0.00242	CcSEcCtD
Duloxetine—Erythema multiforme—Docetaxel—head and neck cancer	0.00128	0.0024	CcSEcCtD
Duloxetine—Headache—Vinblastine—head and neck cancer	0.00127	0.00238	CcSEcCtD
Duloxetine—Anorexia—Fluorouracil—head and neck cancer	0.00127	0.00238	CcSEcCtD
Duloxetine—Diarrhoea—Hydroxyurea—head and neck cancer	0.00126	0.00237	CcSEcCtD
Duloxetine—Eye disorder—Docetaxel—head and neck cancer	0.00126	0.00237	CcSEcCtD
Duloxetine—Flushing—Docetaxel—head and neck cancer	0.00125	0.00235	CcSEcCtD
Duloxetine—Cardiac disorder—Docetaxel—head and neck cancer	0.00125	0.00235	CcSEcCtD
Duloxetine—Angiopathy—Docetaxel—head and neck cancer	0.00123	0.0023	CcSEcCtD
Duloxetine—Dizziness—Hydroxyurea—head and neck cancer	0.00122	0.00229	CcSEcCtD
Duloxetine—Immune system disorder—Docetaxel—head and neck cancer	0.00122	0.00229	CcSEcCtD
Duloxetine—Mediastinal disorder—Docetaxel—head and neck cancer	0.00122	0.00228	CcSEcCtD
Duloxetine—Chills—Docetaxel—head and neck cancer	0.00121	0.00227	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00121	0.00227	CcSEcCtD
Duloxetine—Arrhythmia—Docetaxel—head and neck cancer	0.00121	0.00226	CcSEcCtD
Duloxetine—Nausea—Vinblastine—head and neck cancer	0.0012	0.00226	CcSEcCtD
Duloxetine—Insomnia—Fluorouracil—head and neck cancer	0.0012	0.00226	CcSEcCtD
Duloxetine—Paraesthesia—Fluorouracil—head and neck cancer	0.00119	0.00224	CcSEcCtD
Duloxetine—Alopecia—Docetaxel—head and neck cancer	0.00119	0.00224	CcSEcCtD
Duloxetine—Mental disorder—Docetaxel—head and neck cancer	0.00118	0.00222	CcSEcCtD
Duloxetine—Somnolence—Fluorouracil—head and neck cancer	0.00118	0.00222	CcSEcCtD
Duloxetine—Malnutrition—Docetaxel—head and neck cancer	0.00118	0.00221	CcSEcCtD
Duloxetine—Erythema—Docetaxel—head and neck cancer	0.00118	0.00221	CcSEcCtD
Duloxetine—Vomiting—Hydroxyurea—head and neck cancer	0.00117	0.0022	CcSEcCtD
Duloxetine—Dyspepsia—Fluorouracil—head and neck cancer	0.00117	0.0022	CcSEcCtD
Duloxetine—Rash—Hydroxyurea—head and neck cancer	0.00116	0.00219	CcSEcCtD
Duloxetine—Dermatitis—Hydroxyurea—head and neck cancer	0.00116	0.00218	CcSEcCtD
Duloxetine—Headache—Hydroxyurea—head and neck cancer	0.00116	0.00217	CcSEcCtD
Duloxetine—Decreased appetite—Fluorouracil—head and neck cancer	0.00116	0.00217	CcSEcCtD
Duloxetine—Dysgeusia—Docetaxel—head and neck cancer	0.00115	0.00216	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00115	0.00215	CcSEcCtD
Duloxetine—Back pain—Docetaxel—head and neck cancer	0.00114	0.00213	CcSEcCtD
Duloxetine—Pain—Fluorouracil—head and neck cancer	0.00114	0.00213	CcSEcCtD
Duloxetine—Muscle spasms—Docetaxel—head and neck cancer	0.00113	0.00212	CcSEcCtD
Duloxetine—Nausea—Hydroxyurea—head and neck cancer	0.0011	0.00206	CcSEcCtD
Duloxetine—Feeling abnormal—Fluorouracil—head and neck cancer	0.0011	0.00206	CcSEcCtD
Duloxetine—Anaemia—Docetaxel—head and neck cancer	0.00109	0.00204	CcSEcCtD
Duloxetine—Urticaria—Fluorouracil—head and neck cancer	0.00106	0.00198	CcSEcCtD
Duloxetine—Syncope—Docetaxel—head and neck cancer	0.00105	0.00198	CcSEcCtD
Duloxetine—Leukopenia—Docetaxel—head and neck cancer	0.00105	0.00197	CcSEcCtD
Duloxetine—Body temperature increased—Fluorouracil—head and neck cancer	0.00105	0.00197	CcSEcCtD
Duloxetine—Palpitations—Docetaxel—head and neck cancer	0.00104	0.00195	CcSEcCtD
Duloxetine—Loss of consciousness—Docetaxel—head and neck cancer	0.00103	0.00194	CcSEcCtD
Duloxetine—Cough—Docetaxel—head and neck cancer	0.00103	0.00193	CcSEcCtD
Duloxetine—Convulsion—Docetaxel—head and neck cancer	0.00102	0.00191	CcSEcCtD
Duloxetine—Hypertension—Docetaxel—head and neck cancer	0.00102	0.0019	CcSEcCtD
Duloxetine—Arthralgia—Docetaxel—head and neck cancer	0.001	0.00188	CcSEcCtD
Duloxetine—Chest pain—Docetaxel—head and neck cancer	0.001	0.00188	CcSEcCtD
Duloxetine—Myalgia—Docetaxel—head and neck cancer	0.001	0.00188	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000994	0.00187	CcSEcCtD
Duloxetine—Hypersensitivity—Fluorouracil—head and neck cancer	0.00098	0.00184	CcSEcCtD
Duloxetine—Dry mouth—Docetaxel—head and neck cancer	0.000979	0.00184	CcSEcCtD
Duloxetine—Confusional state—Docetaxel—head and neck cancer	0.000968	0.00182	CcSEcCtD
Duloxetine—Anaphylactic shock—Docetaxel—head and neck cancer	0.00096	0.0018	CcSEcCtD
Duloxetine—Oedema—Docetaxel—head and neck cancer	0.00096	0.0018	CcSEcCtD
Duloxetine—Infection—Docetaxel—head and neck cancer	0.000953	0.00179	CcSEcCtD
Duloxetine—Shock—Docetaxel—head and neck cancer	0.000944	0.00177	CcSEcCtD
Duloxetine—Nervous system disorder—Docetaxel—head and neck cancer	0.000941	0.00177	CcSEcCtD
Duloxetine—Pruritus—Fluorouracil—head and neck cancer	0.000941	0.00176	CcSEcCtD
Duloxetine—Thrombocytopenia—Docetaxel—head and neck cancer	0.00094	0.00176	CcSEcCtD
Duloxetine—Tachycardia—Docetaxel—head and neck cancer	0.000937	0.00176	CcSEcCtD
Duloxetine—Skin disorder—Docetaxel—head and neck cancer	0.000932	0.00175	CcSEcCtD
Duloxetine—Anorexia—Docetaxel—head and neck cancer	0.000915	0.00172	CcSEcCtD
Duloxetine—Diarrhoea—Fluorouracil—head and neck cancer	0.00091	0.00171	CcSEcCtD
Duloxetine—Dizziness—Fluorouracil—head and neck cancer	0.000879	0.00165	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000874	0.00164	CcSEcCtD
Duloxetine—Insomnia—Docetaxel—head and neck cancer	0.000868	0.00163	CcSEcCtD
Duloxetine—Paraesthesia—Docetaxel—head and neck cancer	0.000862	0.00162	CcSEcCtD
Duloxetine—Somnolence—Docetaxel—head and neck cancer	0.000853	0.0016	CcSEcCtD
Duloxetine—Vomiting—Fluorouracil—head and neck cancer	0.000845	0.00159	CcSEcCtD
Duloxetine—Dyspepsia—Docetaxel—head and neck cancer	0.000845	0.00158	CcSEcCtD
Duloxetine—Rash—Fluorouracil—head and neck cancer	0.000838	0.00157	CcSEcCtD
Duloxetine—Dermatitis—Fluorouracil—head and neck cancer	0.000838	0.00157	CcSEcCtD
Duloxetine—Decreased appetite—Docetaxel—head and neck cancer	0.000834	0.00157	CcSEcCtD
Duloxetine—Headache—Fluorouracil—head and neck cancer	0.000833	0.00156	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000829	0.00155	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—head and neck cancer	0.000827	0.00155	CcSEcCtD
Duloxetine—Pain—Docetaxel—head and neck cancer	0.000821	0.00154	CcSEcCtD
Duloxetine—Constipation—Docetaxel—head and neck cancer	0.000821	0.00154	CcSEcCtD
Duloxetine—Feeling abnormal—Docetaxel—head and neck cancer	0.000791	0.00148	CcSEcCtD
Duloxetine—Nausea—Fluorouracil—head and neck cancer	0.00079	0.00148	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000785	0.00147	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—head and neck cancer	0.000759	0.00142	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—head and neck cancer	0.000759	0.00142	CcSEcCtD
Duloxetine—Hypersensitivity—Docetaxel—head and neck cancer	0.000707	0.00133	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—head and neck cancer	0.000689	0.00129	CcSEcCtD
Duloxetine—Pruritus—Docetaxel—head and neck cancer	0.000679	0.00127	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—head and neck cancer	0.000657	0.00123	CcSEcCtD
Duloxetine—CYP1A2—Estrogen metabolism—GSTM1—head and neck cancer	0.000645	0.0109	CbGpPWpGaD
Duloxetine—CYP2D6—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000639	0.0108	CbGpPWpGaD
Duloxetine—Dizziness—Docetaxel—head and neck cancer	0.000635	0.00119	CcSEcCtD
Duloxetine—CYP1A2—Estrogen metabolism—CYP1A1—head and neck cancer	0.000612	0.0104	CbGpPWpGaD
Duloxetine—Vomiting—Docetaxel—head and neck cancer	0.00061	0.00114	CcSEcCtD
Duloxetine—Rash—Docetaxel—head and neck cancer	0.000605	0.00114	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—head and neck cancer	0.000605	0.00113	CcSEcCtD
Duloxetine—Headache—Docetaxel—head and neck cancer	0.000601	0.00113	CcSEcCtD
Duloxetine—SLC6A2—NRF2 pathway—TGFA—head and neck cancer	0.000592	0.01	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—MAPK3—head and neck cancer	0.000571	0.00968	CbGpPWpGaD
Duloxetine—Nausea—Docetaxel—head and neck cancer	0.00057	0.00107	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—KISS1—head and neck cancer	0.000568	0.00963	CbGpPWpGaD
Duloxetine—CYP1A2—Xenobiotics—CYP1A1—head and neck cancer	0.000562	0.00953	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—MAPK1—head and neck cancer	0.000544	0.00921	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—KISS1—head and neck cancer	0.000542	0.00918	CbGpPWpGaD
Duloxetine—CYP1A2—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000541	0.00916	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—TGFA—head and neck cancer	0.000525	0.00889	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—KISS1—head and neck cancer	0.000516	0.00875	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—MAPK3—head and neck cancer	0.000496	0.00841	CbGpPWpGaD
Duloxetine—CYP2D6—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000493	0.00836	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.000487	0.00825	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.000485	0.00821	CbGpPWpGaD
Duloxetine—SLC6A3—Dopaminergic Neurogenesis—STAT3—head and neck cancer	0.000475	0.00805	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—MAPK1—head and neck cancer	0.000472	0.008	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—KISS1—head and neck cancer	0.00047	0.00797	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—GRP—head and neck cancer	0.000468	0.00793	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—GRP—head and neck cancer	0.000446	0.00756	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—head and neck cancer	0.000437	0.0074	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—GRP—head and neck cancer	0.000425	0.0072	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.000421	0.00713	CbGpPWpGaD
Duloxetine—CYP1A2—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000418	0.00708	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.000401	0.0068	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—GSTM1—head and neck cancer	0.0004	0.00678	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.000399	0.00676	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—GRP—head and neck cancer	0.000387	0.00656	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—head and neck cancer	0.000379	0.00642	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—KISS1—head and neck cancer	0.000371	0.00629	CbGpPWpGaD
Duloxetine—CYP1A2—Estrogen Receptor Pathway—STAT3—head and neck cancer	0.000368	0.00624	CbGpPWpGaD
Duloxetine—CYP1A2—Phase II conjugation—NAT2—head and neck cancer	0.000367	0.00622	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.000359	0.00608	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.000347	0.00587	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—GSTM1—head and neck cancer	0.000344	0.00583	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TYMS—head and neck cancer	0.000313	0.00531	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.000312	0.00528	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—GRP—head and neck cancer	0.000306	0.00518	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KISS1—head and neck cancer	0.000305	0.00517	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—GSTM1—head and neck cancer	0.000305	0.00516	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.000295	0.00501	CbGpPWpGaD
Duloxetine—CYP1A2—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000289	0.00489	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.000289	0.00489	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	0.000289	0.00489	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000282	0.00478	CbGpPWpGaD
Duloxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000276	0.00467	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—KISS1—head and neck cancer	0.000273	0.00463	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000273	0.00462	CbGpPWpGaD
Duloxetine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000272	0.00461	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00027	0.00458	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.000257	0.00435	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—NAT2—head and neck cancer	0.000254	0.0043	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GRP—head and neck cancer	0.000251	0.00425	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	0.00025	0.00424	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00025	0.00424	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT6—head and neck cancer	0.000244	0.00413	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—KISS1—head and neck cancer	0.000237	0.00402	CbGpPWpGaD
Duloxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000234	0.00396	CbGpPWpGaD
Duloxetine—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00023	0.0039	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—GRP—head and neck cancer	0.000225	0.00381	CbGpPWpGaD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000223	0.00379	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—YAP1—head and neck cancer	0.000216	0.00366	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—NAT2—head and neck cancer	0.000215	0.00364	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—NAT2—head and neck cancer	0.000212	0.00359	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—KISS1—head and neck cancer	0.00021	0.00355	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—GRP—head and neck cancer	0.000195	0.00331	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KISS1—head and neck cancer	0.00019	0.00323	CbGpPWpGaD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000189	0.00321	CbGpPWpGaD
Duloxetine—CYP1A2—Phase II conjugation—GSTM1—head and neck cancer	0.000181	0.00307	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—GRP—head and neck cancer	0.000173	0.00293	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	0.000172	0.00291	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000169	0.00285	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000161	0.00272	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.000159	0.0027	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GRP—head and neck cancer	0.000157	0.00266	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—KISS1—head and neck cancer	0.000154	0.00262	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—PTEN—head and neck cancer	0.000152	0.00258	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KISS1—head and neck cancer	0.00014	0.00238	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000135	0.00229	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—KISS1—head and neck cancer	0.000134	0.00227	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GRP—head and neck cancer	0.000127	0.00215	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	0.000125	0.00212	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—IL2—head and neck cancer	0.000125	0.00211	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	0.000124	0.00209	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000122	0.00206	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000122	0.00206	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.000122	0.00206	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KISS1—head and neck cancer	0.000122	0.00206	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	0.000119	0.00201	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000117	0.00198	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GRP—head and neck cancer	0.000115	0.00196	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL2—head and neck cancer	0.000113	0.00192	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KISS1—head and neck cancer	0.000112	0.00191	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GRP—head and neck cancer	0.00011	0.00187	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	0.000106	0.0018	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	0.000105	0.00177	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—UROD—head and neck cancer	0.000104	0.00177	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—head and neck cancer	0.000104	0.00176	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000101	0.00172	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	0.000101	0.0017	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GRP—head and neck cancer	0.0001	0.0017	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	9.92e-05	0.00168	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	9.78e-05	0.00166	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NOTCH1—head and neck cancer	9.72e-05	0.00165	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—MAPK1—head and neck cancer	9.47e-05	0.0016	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GRP—head and neck cancer	9.26e-05	0.00157	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—MAPK3—head and neck cancer	9.11e-05	0.00154	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT6—head and neck cancer	8.99e-05	0.00152	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—UROD—head and neck cancer	8.85e-05	0.0015	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—MAPK1—head and neck cancer	8.66e-05	0.00147	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—EGFR—head and neck cancer	8.66e-05	0.00147	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	8.55e-05	0.00145	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KISS1—head and neck cancer	8.28e-05	0.0014	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—PIK3CA—head and neck cancer	8.28e-05	0.0014	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	8.13e-05	0.00138	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	8.13e-05	0.00138	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—YAP1—head and neck cancer	7.96e-05	0.00135	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—PIK3CA—head and neck cancer	7.89e-05	0.00134	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—head and neck cancer	7.6e-05	0.00129	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PIK3CA—head and neck cancer	7.52e-05	0.00127	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	7.42e-05	0.00126	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—MAPK1—head and neck cancer	7.26e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KISS1—head and neck cancer	7.19e-05	0.00122	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	7.06e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	7.06e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	7.06e-05	0.0012	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HRAS—head and neck cancer	6.96e-05	0.00118	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	6.86e-05	0.00116	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—PIK3CA—head and neck cancer	6.85e-05	0.00116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GRP—head and neck cancer	6.82e-05	0.00116	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AKT1—head and neck cancer	6.76e-05	0.00115	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2—head and neck cancer	6.69e-05	0.00113	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT6—head and neck cancer	6.62e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	6.53e-05	0.00111	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCND1—head and neck cancer	6.52e-05	0.00111	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTEN—head and neck cancer	6.3e-05	0.00107	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AKT1—head and neck cancer	6.14e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	6.13e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GRP—head and neck cancer	5.92e-05	0.001	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—YAP1—head and neck cancer	5.86e-05	0.000993	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—HRAS—head and neck cancer	5.83e-05	0.000987	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT6—head and neck cancer	5.75e-05	0.000974	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—head and neck cancer	5.69e-05	0.000963	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	5.67e-05	0.000961	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT3—head and neck cancer	5.63e-05	0.000954	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK3—head and neck cancer	5.38e-05	0.000911	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK1—head and neck cancer	5.12e-05	0.000867	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—head and neck cancer	5.12e-05	0.000867	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—YAP1—head and neck cancer	5.09e-05	0.000862	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—head and neck cancer	4.6e-05	0.00078	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CA—head and neck cancer	4.44e-05	0.000752	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAT2—head and neck cancer	4.34e-05	0.000735	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—head and neck cancer	4.3e-05	0.000728	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—head and neck cancer	4.18e-05	0.000708	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—head and neck cancer	4.11e-05	0.000696	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.9e-05	0.000661	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.86e-05	0.000654	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—DPYD—head and neck cancer	3.8e-05	0.000644	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAT2—head and neck cancer	3.67e-05	0.000622	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—head and neck cancer	3.63e-05	0.000615	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—YAP1—head and neck cancer	3.61e-05	0.000611	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH1—head and neck cancer	3.59e-05	0.000608	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—head and neck cancer	3.39e-05	0.000574	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK3—head and neck cancer	3.36e-05	0.000569	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DPYD—head and neck cancer	3.22e-05	0.000546	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK1—head and neck cancer	3.2e-05	0.000541	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—head and neck cancer	3.2e-05	0.000541	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—head and neck cancer	3.08e-05	0.000521	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—YAP1—head and neck cancer	3.06e-05	0.000518	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—head and neck cancer	3.05e-05	0.000517	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—head and neck cancer	2.94e-05	0.000498	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—head and neck cancer	2.77e-05	0.00047	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—head and neck cancer	2.67e-05	0.000453	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH1—head and neck cancer	2.64e-05	0.000447	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—head and neck cancer	2.57e-05	0.000435	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—head and neck cancer	2.49e-05	0.000423	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—head and neck cancer	2.47e-05	0.000419	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—head and neck cancer	2.47e-05	0.000418	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—head and neck cancer	2.41e-05	0.000408	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK1—head and neck cancer	2.35e-05	0.000399	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—head and neck cancer	2.35e-05	0.000399	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—head and neck cancer	2.32e-05	0.000393	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.3e-05	0.000389	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH1—head and neck cancer	2.29e-05	0.000389	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—head and neck cancer	2.27e-05	0.000384	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—head and neck cancer	2.25e-05	0.000381	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMS—head and neck cancer	2.17e-05	0.000367	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—head and neck cancer	2.15e-05	0.000364	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—head and neck cancer	2.14e-05	0.000363	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—head and neck cancer	2.1e-05	0.000355	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—head and neck cancer	2.08e-05	0.000352	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—head and neck cancer	2.05e-05	0.000347	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK1—head and neck cancer	2.04e-05	0.000346	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—head and neck cancer	2.04e-05	0.000346	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	2.04e-05	0.000346	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A1—head and neck cancer	2.03e-05	0.000344	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—head and neck cancer	1.98e-05	0.000336	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.95e-05	0.000331	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	1.89e-05	0.00032	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK1—head and neck cancer	1.89e-05	0.00032	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—head and neck cancer	1.89e-05	0.00032	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	1.84e-05	0.000311	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMS—head and neck cancer	1.84e-05	0.000311	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—head and neck cancer	1.82e-05	0.000308	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.81e-05	0.000307	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.77e-05	0.0003	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—head and neck cancer	1.77e-05	0.0003	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—head and neck cancer	1.74e-05	0.000294	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.72e-05	0.000291	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.71e-05	0.00029	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.67e-05	0.000283	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	1.64e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—head and neck cancer	1.64e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	1.6e-05	0.00027	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—head and neck cancer	1.58e-05	0.000269	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—head and neck cancer	1.58e-05	0.000267	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.54e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—head and neck cancer	1.54e-05	0.000261	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.53e-05	0.000259	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—head and neck cancer	1.52e-05	0.000257	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—head and neck cancer	1.49e-05	0.000252	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	1.46e-05	0.000248	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	1.45e-05	0.000245	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.41e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	1.39e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—head and neck cancer	1.39e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	1.34e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—head and neck cancer	1.34e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—head and neck cancer	1.33e-05	0.000225	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	1.27e-05	0.000215	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	1.21e-05	0.000205	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—head and neck cancer	1.21e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—head and neck cancer	1.21e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	1.21e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—head and neck cancer	1.17e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—head and neck cancer	1.12e-05	0.000189	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—head and neck cancer	1.05e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	1.05e-05	0.000178	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—head and neck cancer	1.02e-05	0.000173	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—head and neck cancer	1.01e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—head and neck cancer	9.86e-06	0.000167	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—head and neck cancer	9.69e-06	0.000164	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—head and neck cancer	8.92e-06	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—head and neck cancer	8.56e-06	0.000145	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	7.43e-06	0.000126	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—head and neck cancer	6.29e-06	0.000107	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—head and neck cancer	6.07e-06	0.000103	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—head and neck cancer	5.14e-06	8.71e-05	CbGpPWpGaD
